Who are Instillation - EXPAREL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 0.33% ropivacaine 250ml, Lidocaine + Prilocaine, Buffered Lidocaine, Bupivacaine liposomal injectable suspension, Bupivacaine + nalbuphine, Ropivacaine + Midazolam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/instillation-exparel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Instillation - EXPAREL — Competitive Intelligence Brief

Instillation - EXPAREL (Instillation - EXPAREL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting local anesthetic. Area: Pain Management / Anesthesia.

marketed Long-acting local anesthetic Voltage-gated sodium channels Pain Management / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Instillation - EXPAREL (Instillation - EXPAREL) — Pacira Pharmaceuticals, Inc. EXPAREL is a long-acting local anesthetic that blocks sodium channels in nerve fibers to provide prolonged post-operative pain relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Instillation - EXPAREL TARGET	Instillation - EXPAREL	Pacira Pharmaceuticals, Inc	marketed	Long-acting local anesthetic	Voltage-gated sodium channels
0.33% ropivacaine 250ml	0.33% ropivacaine 250ml	Guangzhou General Hospital of Guangzhou Military Command	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine + Prilocaine	Lidocaine + Prilocaine	Galeno Desenvolvimento de Pesquisas Clínicas	marketed	Local anesthetic	Voltage-gated sodium channels
Buffered Lidocaine	Buffered Lidocaine	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine liposomal injectable suspension	Bupivacaine liposomal injectable suspension	The University of Texas Health Science Center, Houston	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Bupivacaine + nalbuphine	Bupivacaine + nalbuphine	Alzahraa Ahmed Abbas	marketed	Local anesthetic + mixed opioid agonist-antagonist	Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)
Ropivacaine + Midazolam	Ropivacaine + Midazolam	Aga Khan University	marketed	Local anesthetic + benzodiazepine combination	Voltage-gated sodium channels (ropivacaine); GABA-A receptors (midazolam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting local anesthetic class)

Pacira Pharmaceuticals, Inc · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Instillation - EXPAREL — Competitive Intelligence Brief. https://druglandscape.com/ci/instillation-exparel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab